<?xml version='1.0' encoding='utf-8'?>
<document id="30433922"><sentence text="The Case-Crossover Design for Drug-Drug Interactions: Considerations for Implementation." /><sentence text="The case-crossover design may be useful for evaluating the clinical impact of drug-drug interactions in electronic healthcare data; however, experience with the design in this context is limited" /><sentence text="" /><sentence text="Using US healthcare claims data (1994-2013), we evaluated two examples of interacting drugs with prior evidence of harm: (1) cytochrome P450 (CYP)3A4-metabolized statins + clarithromycin or erythromycin and rhabdomyolysis; and (2) clopidogrel + fluoxetine or fluvoxamine and ischemic events"><entity charOffset="172-186" id="DDI-PubMed.30433922.s4.e0" text="clarithromycin" /><entity charOffset="190-202" id="DDI-PubMed.30433922.s4.e1" text="erythromycin" /><entity charOffset="231-255" id="DDI-PubMed.30433922.s4.e2" text="clopidogrel + fluoxetine" /><entity charOffset="259-270" id="DDI-PubMed.30433922.s4.e3" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.30433922.s4.e0" e2="DDI-PubMed.30433922.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30433922.s4.e0" e2="DDI-PubMed.30433922.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30433922.s4.e0" e2="DDI-PubMed.30433922.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30433922.s4.e0" e2="DDI-PubMed.30433922.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30433922.s4.e1" e2="DDI-PubMed.30433922.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30433922.s4.e1" e2="DDI-PubMed.30433922.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30433922.s4.e1" e2="DDI-PubMed.30433922.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30433922.s4.e2" e2="DDI-PubMed.30433922.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30433922.s4.e2" e2="DDI-PubMed.30433922.s4.e3" /></sentence><sentence text=" We conducted case-crossover analyses with (1) a three-parameter model with a product term and a six-parameter saturated model that distinguished initiation order of the two drugs; and (2) with or without active comparators" /><sentence text="" /><sentence text="In the statin example, the three-parameter model produced estimates consistent with prior evidence with the active comparator (product term odds ratio [OR] = 2" /><sentence text="05, 95% confidence interval [CI] = 1" /><sentence text="00, 4" /><sentence text="23) and without (OR = 1" /><sentence text="99, 95% CI = 1" /><sentence text="04, 3" /><sentence text="81)" /><sentence text=" In the clopidogrel example, this model produced results opposite of expectation (OR = 0"><entity charOffset="8-19" id="DDI-PubMed.30433922.s14.e0" text="clopidogrel" /></sentence><sentence text="78, 95% = 0" /><sentence text="68, 0" /><sentence text="89), but closer to what was observed in prior studies when active comparator was used (OR = 1" /><sentence text="03, 95% CI = 0" /><sentence text="90, 1" /><sentence text="19)" /><sentence text=" The saturated model revealed heterogeneity of estimates across strata and considerable confounding; strata with concordant clopidogrel exposure likely produced the least biased estimates"><entity charOffset="124-135" id="DDI-PubMed.30433922.s21.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="The three-parameter model assumes a common drug-drug interaction effect, whereas the saturated model is useful for identifying potential effect heterogeneity or differential confounding across strata" /><sentence text=" Restriction to certain strata or use of an active comparator may be necessary in the presence of within-person confounding" /><sentence text="" /></document>